Summary
The influence of variations in sodium chloride diet, furosemide and acetazolamide on nephrotoxicity induced by cisplatinum have been investigated in the rat by measuring serum creatinine concentrations 5 days after cisplatinum (5 mg/kg, ip) administration. Sodium chloride depletion enhanced, while sodium chloride loading minimized changes in renal function. Increases in urine flow rate following a dextrose water load failed to alter the nephrotoxic response. Both furosemide and acetazolamide, given 30 min before cisplatinum, attenuated the nephrotoxic response. In contrast, neither sodium chloride loading, furosemide, nor acetazolamide influenced the change in renal function when given 30 min after cisplatinum. These observations indicate that renal damage due to cisplatinum can be modified by alterations in dietary salt and by diuretics and that the extent of ultimate renal damage is dependent on factors occurring immediately after cisplatinum administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Choie DD, DelCampo AA, Guarino AM (1980) Subcellular localization of cisdichlorodiammine platinum (II) in rat kidney and liver. Toxicol Appl Pharmacol 55:245–252
Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF (1977) Improvement of cis-dichlorodimmineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 39:1357–1361
Dentino M, Luft FC, Yum MN, Williams SD, Einhorn LH (1978) Long term effect of cis-diamminedichlorideplatinum (CDDP) on renal function and structure in man. Cancer 41:1274–1281
Earhart RH, Martin PA, Tutsch KD, Erlürk E, Wheeler RH, Bull FE (1983) Improvement in the therapeutic index of cisplatin (NSC 119875) by pharmacologically induced chloruresis in the rat. Cancer Res 43:1187–1194
Einhorn LH, Donohue J (1977) Cisdiamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Int Med 87:293–298
Gerkens J, Branch RA (1980) The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity. J Pharm Exp Ther 214:306–311
Goldstein RS, Mayor GH (1982) Minireview: The nephrotoxicity of cisplatinum. Life Sci 32:685–690
Goldstein RS, Noordewier B, Bond JT, Hook JB, Mayor GH (1981) Cisdichlorodiammineplatinum nephrotoxicity: time course and dose response of renal functional impairement. Toxicol Appl Pharmacol 60:163–175
Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS (1977) The renal pathology in clinical trials of cisplatinum (II) diamminedichloride. Cancer 39:1362–1371
Hayes DM, Cvitkovic E, Golbey RB, Schiener E, Helson L, Krakoff IH (1977) High dose cis-platinum diammine dichloride: Amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372–1381
Howell SB, Taetle R (1980) Effect of sodium thiosulfate on cisdichlorodiammine platinum (II) toxicity and antitumor activity in L 1210 leukemia. Cancer Treat Rep 64:611–616
Kociba RJ, Sleight SD (1971) Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC 119875). Cancer Chemother Rep 55:1–8
Lehane D, Winston A, Gray R, Daskal Y (1979) The effect of diuretic pretreatment on clinical, morphological and ultrastructural cis-platinum induced nephrotoxicity. Int J Radiation Oncology Biol Phys 5:1343–1399
Leonard BJ, Eccleston E, Jones D, Todd P, Walpole A (1971) Antileukaemic and nephrotoxic properties of platinum compounds. Nature (Lond) 234:43–45
Lippman AJ, Helson C, Helson L, Krakoff IH (1973) Clinical trials of cisdiamminedichloroplatinum. Cancer Chemother Rep 57:191–200
Litterst CL (1981) Alterations in the toxicity of cisdichlorodiammine platinum (II) and in tissue localization of platinum as a function of NaCl concentrations in the vehicle of administration. Toxicol Appl Pharmacol 61:99–108
Litterst CL, Gram TE, Dedrick RL, Leroy AF, Guarino AM (1976) Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum (II) (NSC 119875) to dogs. Cancer Res 36:2340–2344
Madias NE, Harrington JT (1978) Platinum nephrotoxicity. Am J Med 65:307–314
Pera MF, Zook BC, Nader HC (1979) Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammine platinum-(II) in rats. Cancer Res 39:1269–1278
Rossof AH, Salyton RE, Perla CP (1977) Preliminary clinical experience with cisdiamminedichloroplatinum (II). Cancer 30:1451–1456
Rozencweig M, Von Hoff DD, Slavik M, Muggia FM (1977) Cisdiamminedichloroplatinum (II). A new anti-cancer drug. Ann Int Med 86:803–812
Safirstein R, Miller P, Dikman S, Lyman N, Shapiro C (1981) Cisplatin nephrotoxicity in rats: defect in papillary hypertonicity. Am J Physiol 241:F175-F185
Schaeppi U, Heyman IA, Fleishman RW, Rosenkrantz H, Ilievski V, Phelan R, Cooney DA, Davies RD (1973) Cis-Dichlorodiammineplatinum (II) (NSC-119875): preclinical toxicologic evaluation of intravenous injection in dogs, monkeys, and mice. Toxicol Appl Pharmacol 25:230–241
Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, Muggia RF (1979) Toxic effects of cisdichlorodiammineplatinum (II) in man. Cancer Treat Rep 63:1527–1531
Ward JM, Fauvie KA (1976) The nephrotoxic effects of cisdiamminedichloroplatinum (II) (NSC-119875) in male F344 rats. Toxicol Appl Pharmacol 38:535–547
Ward JM, Grabin ME, Berlin E, Young DM (1977) Prevention of renal failure in rats receiving cis-diamminedichloroplatinum (II) by administration of furosemide. Cancer Res 37:1238–1240
Author information
Authors and Affiliations
Additional information
This work is supported by USPHS Grant No. HL 14192. E. K. Jackson is an Established Investigator of the American Heart Association. H. Heidemann has Fellowship support from Deutsche Forschungsgemeinschaft
Rights and permissions
About this article
Cite this article
Heidemann, H.T., Gerkens, J.F., Jackson, E.K. et al. Attenuation of cisplatinum-induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide. Naunyn-Schmiedeberg's Arch. Pharmacol. 329, 201–205 (1985). https://doi.org/10.1007/BF00501213
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00501213